References
- 1. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.Genes Chromosomes Cancer. 1997; 20(4): 399-407.
- 2. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998; 20(2): 207-211.
- 3. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res. 2006; 8(3): 210-219.
- 4. Curtis C, Lynch AG, Dunning MJ, et al. The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics. 2009; 10: 588-610.
- 5. Bertucci F, Houlgatte R, Nguyen C, Viens P, Jordan BR, Birnbaum D. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol. 2001; 2(11): 674-682.
- 6. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747-752.
- 7. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19): 10869-10874.
- 8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360(8): 790-800.
- 9. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362(9381):362-369.
- 10. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004; 22(12): 2284-2293.
- 11. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007; 8(12): 1071-1078.
- 12. Farmer P, Bonnefoi H, Anderle P, et al. A stromarelated gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 5(1): 68-74.
- 13. Dunn L, Demichele A. Genomic predictors of outcome and treatment response in breast cancer. Diagn Mol Ther. 2009; 13(2): 73-90.
- 14. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008; 8: 299-313.
- 15. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006; 45(11): 1033-1040.
- 16. Chin K, de Vries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10(6): 529-541.
- 17. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006; 38(12): 1386-1396.
- 18. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6): 515-527.
- 19. Adélaïde J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007; 67(24): 11565-11575.
- 20. Chin SF, Teschendorff AE, Marioni JC, et al. Highresolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007; 8(10): R215-R231.
- 21. Bernard-Pierrot I, Gruel N, Stransky N, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res. 2008; 68(17): 7165-7175.
- 22. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008; 14(7): 1956-1965.
- 23. André F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009; 15(2): 441-451.
- 24. Horlings HM, Lai C, Nuyten DS, et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res. 2010; 16(2): 651-663.
- 25. Popovici C, Basset C, Bertucci F, et al. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer. 2002; 35(3): 204-218.
- 26. Adélaïde J, Huang HE, Murati A, et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer targets the heregulin/NRG1 gene at 8p12. Genes Chromosomes Cancer. 2003; 37(4): 333-345.
- 27. Huang HE, Chin S-F, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/ neuregulin 1/heregulin gene. Cancer Res. 2004; 64(19): 6840-6844.
- 28. Letessier A, Ginestier C, Charafe-Jauffret E, et al. ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer. 2005; 44(1): 103-108.
- 29. Letessier A, Garrido-Urbani S, Ginestier C, et al. Correlated break at PARK2/FRA6E and loss of AF- 6/ Afadin protein expression are associated with poor outcome in breast cancer. Oncogene. 2007; 26(2): 298-307.
- 30. Ginestier C, Bardou V-J, Popovici C, et al. Absence of FHIT protein expression correlates with adverse evolution in good prognosis localized breast cancer. Int J Cancer. 2003; 107(5): 854-862.
- 31. Letessier A, Sircoulomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. 2006; 6(1): 245-257.
- 32. Bekhouche I, Finetti P, Adélaïde J, et al. Genome profiling of inflammatory breast cancer. PLoS One. 2011; 6(2): e16950-16962.
- 33. Sircoulomb F, Bekhouche I, Finetti P, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010; 10: 539-556.
- 34. Addou-Klouche L, Adélaïde J, Finetti P, et al. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer. 2010; 9(1): 213-225.
- 35. Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 2011; 3(3): 153-166.
- 36. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6): 415-428.
- 37. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004; 18(19): 2315-2335.
- 38. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007; 26(47): 6697-6714.
- 39. Goll MG, Bestor TH. Histone modification and replacement in chromatin activation. Genes Dev. 2002; 16(14): 1739-1742.
- 40. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006; 31(2): 89-97.
- 41. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16(Spec 1): R50-R59.
- 42. Wildschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21(35): 5462-5482.
- 43. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: The time is now. Crit Rev Oncol Hematol. 2008; 68(1): 1-11.
- 44. Ordway JM, Budiman MA, Korshunova Y, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One. 2007; 2(12): e1314-1325.
- 45. Bediaga NG, Acha-Sagredo A, Guerra I, et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010; 12(5): R77-R78.
- 46. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010; 12 (3): R36-R51.
- 47. van der Auwera I, Yu W, Suo L, et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One. 2010; 5(9): e12616-12625.
- 48. Fackler MJ, Umbricht CB, Williams D, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 2011; 71(19): 6195-6207.
- 49. Hill VK, Ricketts C, Bieche I, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011; 71(8): 2988-2999.